Journal of Oncology Therapeutics and Drug Development

Dr. Mahmoud K. Singer is a scientist specializing in cancer immunotherapy, translational oncology, and tumor immunology. He serves as a Project Scientist at the University of California, Irvine School of Medicine, where his work focuses on developing new therapies for solid tumors. He earned his Ph.D. in Biochemistry and Immunology from Egypt and has held research positions at the City of Hope National Medical Center, contributing to studies on immune regulation in multiple myeloma and solid tumors. He is a certified in advanced immunoprofiling, with experience spanning preclinical animal studies, clinical immunomonitoring, and translational immunotherapy design. His scientific contributions include more than 30 peer-reviewed publications in leading journals such as Cancers, Cells, Frontiers in Immunology, and Blood, and a U.S. patent application on immune stability modeling. Dr. Singer also serves as a peer reviewer for over 60 international journals.

Dr. Lucia Quaglietta, MD, PhD, is Director of the Neuro-Oncology Unit at AORN Santobono-Pausilipon Children’s Hospital in Naples, Italy. She obtained her Medical Degree, Residency in Pediatrics, and PhD in Human Development, Reproduction and Growth at the University of Naples “Federico II.”
Her main clinical and research interests include pediatric brain tumors, particularly medulloblastoma, ependymoma, diffuse midline glioma, and optic pathway glioma. Dr. Quaglietta serves as Principal Investigator or Co-Investigator in several international multicenter clinical trials within the SIOP Europe framework and actively contributes to translational research on tumor biology and innovative therapeutic approaches.
She has authored numerous peer-reviewed papers and book chapters in pediatric neuro-oncology and is committed to advancing multidisciplinary and precision-medicine strategies in the care of children with central nervous system tumors.

Dr. Christos Diamantopoulos is a Consultant Urologist at the General Hospital of Katerini, Greece. He completed his medical degree at the Democritus University of Thrace, followed by a Master of Science (MSc) in Human Reproduction. He trained extensively in Urology at the General Hospital of Thessaloniki "Papageorgiou" and received the Urology Specialty Title in 2025. He has pursued advanced training in uro-oncology, minimally invasive surgery, and reproductive medicine, and actively contributes as a reviewer in international journals.

Dr. Meng-Yao Li is currently serving as an assistant professor at Renji Hospital Affiliated to Shanghai Tong University School of Medicine. He obtained his graduate degree from the prestigious Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, under the esteemed guidance of Prof. Guo-Qiang Lin. Li has made significant contributions to various scientific publications in renowned journals such as Aggregate, Sci. China Chem., Angew. Chem. Int. Ed., Nat. Commun., Green Chem., iScience, Org. Lett., and Chem. Commun. His research output comprises more than 30 SCI papers that have garnered a total citation count of 500, resulting in a personal H-index value of 13. His research interests are investigating green synthesis, solvent-free and catalyst-free reaction; exploring drug design, synthesis, and their antitumor properties; developing and utilizing patient-derived organoid models as well as patient-derived tumor xenografts; studying drug resistance mechanisms in biliary and pancreatic tumors.

Dr. Tushar Pandey MBBS, MD, DM (Clinical Hematology) a Clinical Hematologist, Hemato-Oncologist, and Bone Marrow Transplant (BMT) & CAR-T Cell Therapy Physician, serving as Director & Head of the Raghav Institute of Hematology, Hemato-Oncology & BMT (R.I.H.O.B) under Raghav Healthcare, Haldwani, Uttarakhand. The region’s first dedicated Hematology Institute.
He is the first DM-certified Clinical Hematologist from Kumaon and adjoining areas of Uttar Pradesh, with specialized training from PGIMER Chandigarh, IMS & SUM Hospital Bhubaneswar, Johns Hopkins University (USA), Imperial College London, and EBMT Europe.

Dr. Pandey has successfully performed over 50 stem cell transplants and multiple CAR-T therapies, with expertise spanning benign and malignant hematological disorders including leukemia, lymphoma, myeloma, thalassemia, hemophilia, and ITP.

He also serves as Program Director of Hemato-Oncology at the International Association for Integrated Oncology (IAIO) and has authored over 15 publications in reputed national and international journals